News for Invex Therapeutics Ltd (IXC.AX)

Christmas is fast approaching and the ASX200 has been down 0.35% at 8,267 points, and the Santa rally has so far failed to materialise.

Invex has reported success simulating the use of Exenatide to improve cell survival in a 3D 'human brain model' of Alzheimer's disease (AD.)

Invex Therapeutics (ASX:IXC) has reported lower-than-expected enrolments for its IIH EVOLVE phase III trial for patients with idiopathic IIH.

Invex Therapeutics (ASX:IXC) has been granted orphan drug designation from the EMA for Exenatide to treat moderate to severe TBI.

Tesla shares were sold after Elon Musk told analysts in an earnings call yesterday that he will keep cutting prices.

Healius (ASX:HLS) has confirmed the receipt of an off-market takeover bid from Australian Clinical Labs (ASX:ACL).

Invex Therapeutics (ASX:IXC) has achieved another key milestone in its efforts to commercialise its Presendin drug to treat neurological conditions related to raised intracranial pressure.

UBS will buy rival Swiss bank Credit Suisse (CS) for 3 billion Swiss francs (US$3.23 billion), which includes $US5.4 billion in losses.

These are the ASX health stocks who are on the verge of completing Phase III trials. Stockhead reaches out to Cynata's Jolanta Airey.

Invex Therapeutics (ASX:IXC) has activated its first US clinical site for its clinical trials to treat intracranial pressure.

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has randomised the first idiopathic intracranial hypertension (IIH) patient into its IIH Evolve Phase III clinical trial using lead drug Presendin.

Australia's longest-suffering tech investors, how green is Woodside's hydrogen plan, and the reality of biofuel coming to save us all.

Closing Bell: ASX 200 sinks, jobless rate hits a 48-year low

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has confirmed it will proceed with a single, Phase III clinical trial to achieve global registration of lead drug Presendin in the treatment of idiopathic intracranial hypertension (IIH).

Neurology specialist Invex Therapeutics (ASX:IXC) soared after announcing it’s about to launch a Phase 3 clinical trial of Presendin.

Global worries and the surprise resignation of NSW Premier Gladys Berejiklian took a heavy toll on the Australian share market, starting the month of October with an unwelcome fall of 2%.

Brickworks boss Lindsay Partridge on Evergrande, the hottest battery IPO listing right now, and questions to ask before investing in a stock.

Closing Bell: ASX shrugs off some sharp falls in uranium stocks to close in the green

A hamster in the US has a portfolio up by around 20% since June, outpacing the S&P500 and Warren Buffett's Berkshire Hathaway.